Disclaimer: this software uses AI to aggregate and filter content. Please double-check sources before putting info to action.
📰 News Media
- ⚠️ [National] Potent ‘Orphine' Opioids Surge in US Illicit Drug Supply - medscape.com
- ⚖️ [National] What to know about 7-OH, MGPI, the synthetic kratom extracts known as 'gas station opioid' - thehill.com
- 🧹 [Biddeford, ME] Biddeford looks to mitigate rising complaints of needle waste, public encampments - pressherald.com
- 💰 [Washington Township, NJ] Washington Township spent opioid settlement funds on license plate cams, police SUVs, according to NJ.com investigation - inquirer.com
- 🏠 Dry, damp, wet - recoveryreview.blog
🗣️ Social Pulse
Lived/Living Experience
Innovation
- 💊 We are honored to share that PBS News featured Quel's Co-Founder and Chief Medical Officer Steven Klein MD, PhD, FASAM, FAAP, FACMG and his work leveraging GLP-1s off-label for addiction as part of their multi-day... - @quel-health on LinkedIn
- 📊 Your pizza has a tracker. Federal #overdose policy deserves one, too. Our new tracker brings federal actions, deadlines and implications for treatment, harm reduction and funding into one place. Download the tracker... - @ActionForOD on X
Opposition Views
- No posts found today.
🏙 City Updates
📧 - [Philadelphia, PA] - October 9, 2026 - PDPH Update: New ICD-10-CM codes for documenting medetomidine toxicity available - newsletter
EXCERPT: "- As of October 1, 2026, new ICD-10-CM codes for documenting medetomidine toxicity are approved for use.
- Medetomidine toxicity is characterized by bradycardia and prolonged sedation, often occurring with opioid overdose.
- Healthcare organizations should implement the new medetomidine toxicity ICD-10-CM codes in their electronic medical records and clinical protocols.
- The update introduces a new subcategory for medetomidine toxicity and associated manifestations such as bradycardia and somnolence.
- For more resources, see the Health Information Portal at [Health Information Portal](https://hip.phila.gov/health-alerts/)."
🔗 Click to sign up for the Philadelphia, PA newsletter.
📚 Academic Research
- 🤝 A sustainable profession: a qualitative exploration of peer experiences and the value of lived experience among the peer support workforce - Substance Abuse Treatment Prevention and Policy - 2026-10-07 - doi.org
- 🩺 Hepatitis C self-testing for people who inject drugs in South Africa and beyond: a catalytic innovation or red herring? - Zenodo (CERN European Organization for Nuclear Research) - 2026-10-07 - doi.org
- 💊 Implementation of Buprenorphine After X-Waiver Elimination: A Health System Review of Rural North Carolina - American Journal of Undergraduate Research - 2026-10-08 - doi.org
⚖️ Law & Policy
- No hits in Law and Policy today.
💸 Funding
Current
- 🛠️ Bureau of Justice Assistance - BJA FY 2026 Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) Training and Technical Assistance (TTA) - Deadline: Nov 2, 2026
- NEW🧒 Office of Juvenile Justice Delinquency Prevention - OJJDP FY 2026 Mentoring for Youth Impacted by Opioids and Other Substance Use - Deadline: Nov 16, 2026
- NEW🧒 Office of Juvenile Justice Delinquency Prevention - OJJDP FY 2026 Opioid Affected Youth Initiative - Deadline: Nov 16, 2026
- 🔬 National Institutes of Health - HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed) - Deadline: Jan 26, 2027
- 🔬 National Institutes of Health - HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) - Deadline: Jan 26, 2027
- 🔬 National Institutes of Health - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) - Deadline: Jun 16, 2028
- 🔬 National Institutes of Health - Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) - Deadline: Aug 21, 2028
- 🔬 National Institutes of Health - Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional) - Deadline: Sep 25, 2028
- 🔬 National Institutes of Health - HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) - Deadline: Feb 9, 2029
- 🏥 Hearst Foundations - Health - Hearst Foundations Health Grants - Minimum grant size is $100,000; consult the Grant Recipients Database for comparable recent awards. - Deadline: Year-round rolling application; no deadlines.
- 🤝 Hearst Foundations - Social Service - Hearst Foundations Social Service Grants - Minimum grant size is $100,000; consult the Grant Recipients Database for recent comparable award amounts. - Deadline: Year-round rolling application; no deadlines.